Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits.

Details

Ressource 1Download: 29296621_BIB_73E580433B39.pdf (202.20 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_73E580433B39
Type
Article: article from journal or magazin.
Collection
Publications
Title
Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits.
Journal
Annals of clinical and translational neurology
Author(s)
Perrotta G., Bonnier G., Meskaldji D.E., Romascano D., Aydarkhanov R., Daducci A., Simioni S., Cavassini M., Metral M., Lazeyras F., Meuli R., Krueger G., Du Pasquier R.A., Granziera C.
ISSN
2328-9503 (Print)
ISSN-L
2328-9503
Publication state
Published
Issued date
12/2017
Peer-reviewed
Oui
Volume
4
Number
12
Pages
915-920
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown. To assess whether rivastigmine therapy is associated with decreased brain inflammation and damage, we performed T1/T2* relaxometry and magnetization transfer imaging in 17 aviremic HIV+ patients with minor neurocognitive disorders enrolled on a crossed over randomized rivastigmine trial. Rivastigmine therapy was associated with changes in MRI metrics indicating a decrease in brain water content (i.e., edema reabsorption) and/or reduced demyelination/axonal damage. Furthermore, MRI changes correlated with cognitive improvement on rivastigmine therapy.

Pubmed
Web of science
Open Access
Yes
Create date
15/01/2018 18:01
Last modification date
20/08/2019 14:31
Usage data